New drug cocktail aims to stall pancreatic cancer
NCT ID NCT04887805
First seen Jun 24, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This phase II trial tests whether a combination of lenvatinib (a targeted drug) and pembrolizumab (an immunotherapy) can help keep advanced pancreatic cancer from progressing. The study includes 28 adults whose cancer has not spread further after initial treatment. Participants receive the drugs as maintenance therapy to see if it extends the time before the cancer grows again.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenvatinib and pembrolizumab
- What this could lead to
- If successful, this combination could help keep advanced pancreatic cancer from growing for longer after initial treatment, potentially extending life.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The drugs can cause side effects like fatigue, high blood pressure, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Decades-Old parasite drug help fight pancreatic cancer?
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
- Can a tailored web portal help pancreatic cancer patients exercise and eat better during chemotherapy?
- Home monitoring may keep cancer patients out of the ER
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers